Ryght AI
Category: AI in Healthcare
An enterprise-grade generative AI platform and orchestration layer designed specifically for life sciences to accelerate clinical trials and optimize biopharma workflows. Ryght AI was founded in 2023. The company is led by Simon Arkell. Based in Laguna Beach, United States. Team size: 22. Total funding raised: ~$9M+ (Accenture amount undisclosed). Latest round: Strategic Investment. Key investors include Foothill Ventures, AIX Ventures, Accenture Ventures, Virtue Ventures, IASO Ventures, Top Harvest Capital, Page One Ventures, Heuristic Capital Partners.
- Founded
- 2023
- Headquarters
- Laguna Beach, United States
- Team size
- 22
- Total funding
- ~$9M+ (Accenture amount undisclosed)
Value proposition
Ryght accelerates clinical trials by automating documentation, site selection, and data analysis using secure, hallucination-free generative AI agents ('Agentic AI') and Digital Site Twins.
Products and solutions
Ryght GenAI Platform, Ryght Knowledge (Protocol analysis), Ryght Build (AI agent creation), Ryght Run (Inference), AI Site Twins (Digital replicas of research sites)
Unique value
Combines a secure, enterprise-grade orchestration layer with 'Agentic AI' capable of complex autonomous tasks (like site feasibility analysis) and 'AI Site Twins' to digitize trial locations globally.
Target customer
Biopharmaceutical companies, CROs (Contract Research Organizations), and Academic Medical Centers
Industries served
Life Sciences, Pharmaceuticals, Clinical Research
Technology advantage
Proprietary / patent-pending AI Site Twins (dynamic digital replicas of 100k+ global research sites) plus agentic AI for protocol-to-site matching, feasibility, and activation; SOC 2-compliant GenAI tuned for biomedical/clinical-ops context.
How they differentiate
Ryght focuses specifically on the 'GenAI Orchestration' layer and autonomous agents for site operations, whereas competitors often focus on static data sets or patient-matching specifically. Ryght positions itself as a 'Service-as-Software' for operations.
Main competitors
IQVIA, Castor, Unlearn.AI, Altis Labs, Deep 6 AI (now part of Tempus), Lokavant, H1
Key partnerships
Accenture (Strategic Investment & Go-to-Market), ASCO (CDK Study site selection, May 2026), NVIDIA, Microsoft (Azure Marketplace), Databricks, AWS, QPS Holdings, Cancer Research South Australia, Various Academic Medical Centers
Notable customers
ASCO, Emory University, West Virginia University, USC Keck School of Medicine, Medical College of Wisconsin, QPS Holdings, Cancer Research South Australia
Major milestones
Founded in 2023 as Synthetica Bio, Rebranded to Ryght AI (November 2023), Launched GenAI Platform for Life Sciences (2024), Raised $3M Seed Round led by Foothill Ventures (June 2025), Secured Strategic Investment from Accenture (December 2025), Partnership with QPS Holdings (January 2025), Launched clinical trial site search engine (Apr 2026), ASCO collaboration for CDK Study site selection (May 2026)
Growth metrics
Partnerships with 8+ leading Academic Medical Centers; Strategic investment from Accenture; Over 100,000 research sites in global network
Market positioning
Emerging leader in GenAI-first clinical operations software
Geographic focus
North America (United States) with global reach via CRO partners
Patents and IP
Patent pending (AI Site Twins / dynamic digital site models)
About Simon Arkell
Serial entrepreneur and two-time Olympian (pole vault). Co-founder of seven venture-backed companies including Deep Lens (acquired by Paradigm Health), Predixion Software (acquired by Greenwave Systems), and Versifi. Over 20 years of experience in AI, healthcare technology, and data analytics.
Latest news about Ryght AI
More AI in Healthcare companies
Official website: https://www.ryght.ai